acrylonitrile has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akcakanat, A; Arango, NP; Black, DM; Chen, K; Eterovic, AK; Evans, KW; Litton, JK; Meric-Bernstam, F; Mills, GB; Scott, SM; Tapia, C; Tarco, E; Tripathy, D; Yap, TA; Yuca, E; Zheng, X | 1 |
1 other study(ies) available for acrylonitrile and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors.
Topics: Acrylonitrile; Aniline Compounds; Animals; BRCA1 Protein; BRCA2 Protein; Cell Line, Tumor; Disease Models, Animal; Female; Gene Expression Regulation, Neoplastic; Germ-Line Mutation; Humans; Mice; Phosphoinositide-3 Kinase Inhibitors; Phthalazines; Poly(ADP-ribose) Polymerase Inhibitors; TOR Serine-Threonine Kinases; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2017 |